Introduction
To sustain metabolism, intracellular ATP concentration must be maintained within a narrow range. This is achieved both at the cellular level as well as the systemic level, encompassing intracellular regulation of anabolic and catabolic pathways in addition to substrate storage and release. It has been recently described how this co-ordination may be achieved through the functions of AMP-activated protein kinase (AMPK), a phylogenetically conserved serine/threonine protein kinase. AMPK has been viewed as a signal integrator monitoring systemic and cellular energy status ( ). This kinase is typically, but not exclusively, activated by an increase AMP/ATP ratio. Once activated, AMPK 1
regulates a large number of downstream targets, shutting down anabolic pathways and stimulating catabolic pathways, thus simultaneously sparing limited energy resources and acquiring extra energy. A synergistic response entails inhibition of anabolic pathways that mediate the synthesis of macromolecules such as protein, fatty acids, lipids, cholesterol and glycogen. Concomitantly AMPK stimulates energy providing pathways like -oxidation, glucose uptake and cardiac glycolysis, the net result of AMPK activation being stabilisation of ATP levels and β restoration of energy balance. AMPK acts first by directly affecting key enzymes activities, in glucose and fat metabolism, and second by e.g.
longer-term transcriptional control of key players of these metabolic pathways. Important progress has recently been made in the understanding of the pathophysiological role of AMPK at both the cellular and whole organism level. This is in part due to the development of transgenic and knockout (KO) mouse models, which have made it possible to study distinct physiological functions for AMPK isoforms.
Structure and function of AMPK complexes
AMPK exists as a heterotrimeric complex consisting of a catalytic subunit and two regulatory and subunits ( ). The conventional Author manuscript, published in "Frontiers in bioscience : a journal and virtual library 2009;14:19-44" which bind, together, two molecules of AMP or ATP in a mutually exclusive manner. Binding of AMP (on subunit) activates AMPK via a γ complex mechanism involving direct allosteric activation and phosphorylation of subunit on Thr172 by upstream kinases as the protein α kinase LKB1 (a tumour suppressor whose germline mutations in humans are the cause of Peutz-Jeghers syndrome), the CaMKKIIβ (calmodulin-dependent protein kinase kinase II ) and perhaps also TAK1 (mammalian transforming growth factor -activated kinase) ( ). conservation that suggests that this ancient signaling circuit evolved at least a billion years ago to regulate a wide spectrum of actions on metabolic homeostasis. In mammals, two to three isoforms of each subunit ( 1, 2, 1, 2, 1, 2, 3) encoded by different genes are known α α β β γ γ γ giving rise to a large variety of heterotrimeric combinations, with splice variants (for the 2 and 3 genes) adding to the diversity. Furthermore, γ γ differences in the tissue distribution of catalytic and regulatory isoforms expression patterns have been reported ( ). Thus, recent investigation 1 of isoform composition of AMPK complexes in human skeletal muscle found that only 3 of the 12 theoretically possible AMPK complexes were present ( 2 2 1 2 2 3 1 2 1) and were activated differently depending on exercise intensity and duration ( ). Moreover, a α β γ ≫α β γ =α β γ 4-6 specificity of each catalytic isoforms for their preferentially upstream kinase has been clearly shown both in skeletal muscle ( ) and heart ( ). 7 8 Indeed, in LKB1 / mice, ischemia in the heart and contraction in skeletal muscle were no more able to activate AMPK 2 subunit whereas − − α AMPK 1 activation is only slightly affected. Interestingly, expression of the 3 subunit appeared highly specific to glycolytic skeletal muscle α γ whereas 1 and 2 showed broad tissue distributions. In skeletal muscle, the 2 subunit is also highly expressed but the 1 subunit
predominates in the liver. AMPK 1 and 2-containing complexes account each for about half of total AMPK activity in liver. In adipose tissue, α α AMPK complexes containing the 1 catalytic subunit are mainly expressed whereas, in skeletal and cardiac muscles, AMPK complexes α containing the 2 catalytic subunit are predominant. In addition of differences in tissue distribution, it is now accepted that AMPK complexes α distribution is also regulated at the intracellular level. Indeed, AMPK 2-containing complexes were found in both the nucleus and the α cytoplasm raising the possibility of the direct phosphorylation of co-activators and transcription factors ( , ). In contrast, AMPK 9 10 α 1-containing complexes are predominantly localized in the cytoplasm but have been also observed at the plasma membrane in airway epithelial cells ( ) and carotid body cells ( ). Although the functional significance of different AMPK isoform combination remains unclear, it raised 11 12 important questions about the function of each heterotrimeric AMPK complex in relation with their particular sensitivity to AMP and ATP, subcellular localization and/or specific targets ( ). As a matter of fact, it has been hypothesized that regulation of exercise-induced glucose 13 transport in human skeletal muscle could be rather associated with 2 2 1 than 2 2 3 heterotrimeric complex activation ( ). Recently, it has α β γ α β γ 6 been suggested that isoform combination may also determine subcellular targeting of AMPK and hence targeting substrates. Very fascinatingly, it has been demonstrated that post-translational modification of the 1 subunit may target AMPK complexes to the plasma β membrane ( ). In addition, it was found that plectin, a cytoskeleton linker protein which has been shown to bind the 1 subunit, affects the 14 γ subunit composition of AMPK complexes in differentiated myotubes ( ). Thus, the selective expression of a particular heterotrimeric AMPK 15 complex could determine a specialized cellular and systemic response to different metabolic stresses.
Development of animal models for the study of AMPK functions
As most of the action of AMPK has been described on the basis of incubation of eukaryotic cells with pharmacological activators of AMPK such as 5-aminoimidazole-4-carboxamide riboside (AICAR) and the antidiabetic drug metformin ( ), it has been difficult to assign 16 specific functions for AMPK heterotrimeric complexes since pharmacological activation of AMPK would supposedly concern all AMPK complexes. To answer this question, the use of mouse transgenic and KO models ( ) has proved useful in this respect. The Table 1A and 1B generation of catalytic subunit ( 1 / and 2 / ) knockout animals has emphasized the distinct and critical role for AMPK 1 and AMPK 2 α − − α − − α α catalytic subunit in the control of energy metabolism. Unfortunately, a double knockout is embryonic lethal at ~10.5 days post-conception (BV, unpublished results), but the development of tissue-specific and conditional knockout for AMPK 2 isoform has allowed the generation of α animal models completely lacking hepatic AMPK activity (AMPK 1 2 / mice) by crossing liver-specific AMPK 2 / mice with AMPK
and skeletal muscle, respectively, has enhanced our understanding of AMPK signaling in these tissues. Animal models over-expressing constitutively active forms of AMPK (mutated form of the 2 or 1 subunit) in liver and skeletal muscle have been also generated and provide α γ useful models for the study of acute and chronic activation of AMPK. In addition to all these mammalian genetic models, the consequence of AMPK deletion or over-expression in the and model systems has been described very recently and gain insight into the C. elegans Drosophila multiple roles of AMPK in the regulation of energy metabolism and other physiological processes.
Distinct physiological roles for 1/2 catalytic subunits of AMPK in the control of whole-body energy metabolism and insulin sensitivity Table 2 altered at the whole-body level by the deletion of either AMPK 2 or AMPK 1 subunits. At this time, how can one explain that lack of AMPK α α α 2 subunit can alter both insulin sensitivity and insulin secretion ? It is now established that impaired insulin action and reduced in vivo in vivo insulin secretion observed in AMPK 2 / mice are both linked to altered function of the autonomic nervous system in integrating peripheral α − − metabolic signals. Indeed, increase in catecholamine release in AMPK 2 / mice could explain development of insulin resistance and glucose α − − intolerance ( ). This suggested that the hypothalamic AMPK 2 contributes to the balance between the whole-body metabolic changes in vivo 18 α and the sympathetic tone which in turn regulates the peripheral metabolism.
Role of AMPK in hepatic metabolism
Hepatic metabolism plays a key role in the control of whole-body energy status since liver is the major site for storage and release of carbohydrates and for the synthesis of fatty acid. In the liver, AMPK coordinates the changes in the activity of enzymes of the lipid metabolism and, so, regulates the partitioning of fatty acids between oxidative and biosynthetic pathways. In the cholesterol synthesis pathway, AMPK phosphorylates and inhibits hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase blocking the conversion of HMG-CoA to mevalonate. In total and liver-specific AMPK 2 / mice, plasma levels for total and HDL cholesterol are not statistically different compared to α − − controls but have a tendency to be higher. This suggested that remaining 1 subunit activity in AMPK 2 / mice is sufficient to control hepatic α α − − cholesterol synthesis and that HMG-CoA reductase is probably a target for both AMPK catalytic subunits. Acetyl-CoA carboxylase (ACC) is an important ratecontrolling enzyme for the synthesis of malonyl-CoA, which is both a critical precursor for biosynthesis of fatty acids and a potent inhibitor of mitochondrial fatty acid oxidation. Phosphorylation and inhibition of ACC by AMPK leads to a fall in malonyl-CoA content and a subsequent decrease in triglyceride synthesis concomitantly with an increase in -oxidation. This was first evidenced by the decrease in β plasma triglyceride levels during AICAR infusion in lean and obese rodents. These results are consistent with findings demonstrating ex vivo the AICAR-induced inhibition of mitochondrial glycerol-3-phosphate acyltransferase (GPAT) activity and subsequent inhibition of triacylglycerol synthesis ( ). In addition, overexpression of AMPK 2 in the liver decreases plasma triglyceride levels and increases plasma 20 α ketone bodies levels, a surrogate marker for hepatic -oxidation ( ). Conversely, liver-specific AMPK 2 deletion leads to increased plasma As reported recently, AMPK has been also involved in the control of mitochondrial biogenesis in the liver. First evidences were brought by treatment with resveratrol, a polyphenol constituent of red wine, which increases mitochondrial number in liver in association with AMPK activation ( ). control HGP and maintain fasting blood glucose levels in the physiological range. In addition, it has been also recently demonstrated that in the absence of hepatic LKB1, AMPK was almost completely inactive and fasting blood glucose levels were highly increased ( ). In liver-specific 27 LKB1 / mice, the antidiabetic drug metformin no longer reduced blood glucose levels providing the apparent possibility that LKB1-mediated
activation of AMPK in the liver might be required to lower blood glucose levels ( ). Knowing the fact that LKB1 regulates thirteen different 27
downstream protein kinases including AMPK, these data raised the question whether glucose-lowering function of LKB1 is mediated by one or several of these AMPK-related kinases rather than AMPK itself. In order to evaluate the respective contribution of AMPK in liver and skeletal muscle for the control of blood glucose levels, mice lacking both 1 and 2 catalytic subunits in the liver (AMPK 1 2 / ) were submitted to correlates with decreased plasma triglycerides, fatty acid concentration and glycerol turnover in both lean and obese rats infused with AICAR (
). This is explained by both HSL phosphorylation on Ser565 in adipocytes and reduction of isoproterenol-induced HSL translocation to the 25 lipid droplet ( ). Whether perilipin is a target of AMPK is presently unknown. Interestingly, in mice lacking the predominant AMPK 1 37 α isoform, the size of adipocytes is reduced and both basal and isoproterenol-induced lipolysis is higher than that of control adipocytes ( ). Even 37
if AMPK 1 subunit is predominant in adipocytes, deletion of AMPK 2 subunit is also followed by modifications in adipose tissue. Indeed, α α AMPK 2 / mice submitted to high fat diet exhibited increased body weight and fat mass ( ). The increase in adipose tissue mass was due to
the enlargement of the pre-existing adipocytes with increased lipid accumulation. This study demonstrates that lack of AMPK 2 subunit may α be a factor contributing to the development of obesity.
Role of AMPK in skeletal muscle
In skeletal muscle, AMPK is activated in response to both endurance exercise ( in rat muscle during treadmill running and in human e.g. without any further increase with exercise training ( ). Moreover, the proportion of type IIa/x fibers in trained AMPK 2i mice was 47 α significantly lower than in their trained controls but no difference for mitochondrial markers was observed in response to exercise training ( ). 47
While it has been known for more than 75 years that physical activity is associated with increased mitochondrial content in muscle, the molecular mechanisms for this adaptive process has only recently been partly elucidated. The first major regulator of mitochondrial biogenesis discovered was PGC-1 which induces mitochondrial biogenesis by activating the transcription of nuclear respiratory factors 1 and 2 and of Table 3 α − − muscles. Coupling between respiratory chain and phosphorylation was also intact in the absence of AMPK 2 in skeletal muscle ( ).
α Table 3 Following endurance training for 8 weeks, an increase of mitochondrial respiration with the addition of different substrates (which became significant with the last addition of substrates, namely pyruvate and glutamate), was observed in the soleus muscle of trained control mice ( , left panel) but not in trained AMPK 2 / soleus muscle ( , right panel). In the case of plantaris muscle, no effect of Figure 4A α − − Endurance training is known to induce a partial fast-to-slow muscle phenotype transformation and mitochondrial biogenesis but no growth.
In contrast, resistance training mainly stimulates muscle protein synthesis resulting in hypertrophy. For muscle growth to occur, the rate of protein synthesis must exceed that of protein breakdown. Since protein synthesis can account for up to 30 50 of the cellular energy -% expenditure, a reduction in protein synthesis seems an efficient mechanism to save energy. One critical signaling pathway controlling protein synthesis during skeletal muscle growth involves the mammalian target of rapamycin (mTOR) kinase. mTOR has emerged as an essential factor for growth and development activated in skeletal muscle by a variety of anabolic signals like resistance exercise. The use of mTOR inhibitor rapamycin has demonstrated that mTOR is required for hypertrophy. On the contrary, AMPK activity is thought to inhibit protein synthesis, which is important for skeletal muscle hypertrophy, and may therefore modulate skeletal muscle mass and hypertrophy ( ). 54
Increased AMPK phosphorylation in fast-twitch plantaris muscle has been associated with an impaired hypertrophic capacity ( , ). In 55 56 parallel, with the mTOR pathway, studies suggest that AMPK reduces both the initiation and the elongation of ribosomal peptide synthesis (57 ) . In rat skeletal muscle, activation of AMPK by AICAR is shown to associate with a reduced protein synthesis ( ). The effect of AMPK on 54 protein synthesis is likely to be due, in part, to AMPK-induced inhibition of the mTOR/ribosomal protein S6 kinase (S6K) signaling pathway ( , ). Indeed, this pathway contains multiple potential sites for regulatory integration with AMPK ( , ). For example, AMPK 54 58-60 54 61
phosphorylates and activates the GAP protein named tuberous sclerosis complex 2 (TSC2). Once activated, TSC2 is able to inactivate its G-protein Rheb thereby blocking activation of mTOR ( , ). It has been also shown that AMPK could directly phosphorylate and inactivate 9 61 mTOR ( ). In parallel, with the mTOR pathway, AMPK reduces protein synthesis by a specific phosphorylation (Ser398) on the eEF-2 kinase 62 ( ), which is a key component in protein synthesis as it promotes peptide elongation. In addition to the AMPK-induced mTOR regulation, it 59
has been recently shown that, on the other way, the suppression of S6K1 activity simultaneously promotes AMPK signaling ( ). 63
Numbers of studies have investigated whether AMPK is an important signaling molecule in the control of skeletal muscle glucose transport. Muscles from AMPK 2 / , AMPK 3 / , AMPK 2-KD and AMPK 2i mice completely abolished AICAR-or
hypoxiastimulated glucose uptake ( , , , ). Based on these observations, AMPK has been proposed to be a key player in initiating 17 19 64 65 signaling to contraction-stimulated glucose uptake. Nevertheless, it has been difficult to verify this hypothesis with genetic approaches. In probably a central role ( ). Interestingly, muscle-specific LKB1 KO mice which lack the ability of AMPK 2 to be phosphorylated and 6 α activated displayed an impaired capacity to stimulate both contraction and AICAR-stimulated glucose uptake ( ). However, these results do not 7
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directly link AMPK activity and glucose transport, as LKB1 phosphorylates and activates several other kinases which could contribute to glucose transport during contraction. Thus, taken together, these data indicate that AMPK can regulate glucose uptake in resting muscle and that AMPK plays, at least partially, a role in the contraction-stimulated glucose uptake.
AMPK is also pivotal in the regulation of skeletal muscle fatty acid metabolism. AMPK activation with AICAR, leptin or adiponectin induces increasing rates of fatty acid oxidation via phosphorylation and inactivation of ACC ( , , ). Interestingly, leptin was found to 29 69 70 selectively activates and phosphorylates AMPK 2 in skeletal muscle via direct and indirect mechanisms; the latter involving the α hypothalamic-sympathetic nervous system and adrenergic receptors in muscle ( ). During muscle contraction, the activation of AMPK Although, pharmacological activation of AMPK in resting muscle has been demonstrated to act on muscle metabolism, the available data from current animal models do not allow to drive firm conclusions about the physiological role of AMPK during exercise and muscle contraction. All the studies using AMPK animal models have brought a quantity of results which are, to some extent, difficult to connect, and even more are contradictory. This conflict could come from the difficulties to compare different genetic animal models. Indeed, expression of a dominant-negative form of AMPK is clearly not equal to the deletion of a particular AMPK subunit. Another reason may be the many additional signaling pathways that are activated during exercise which may have overlapping actions to AMPK. Clearly, more in vivo approaches using new animal models or specific inhibitor strategies are needed to comprehensively understand the role of AMPK in muscle metabolic adaptation during exercise training.
Role of AMPK in the heart
In comparison to hepatic and adipose tissue, the heart could be considered as a simplistic organ, which its function is to be a modest circulating pump. However, this cardiac pump has to continuously adapt its function and, so, its energy consumption to the oxygen demand and circulating substrates and hormones in the body. In normal conditions, the human heart produces and directly consumes 35kg of ATP each day.
This energy comes from the oxidation of different substrates, including fatty acids and glucose ( ). This oxidation requiring a Figure 5A continuous flux of oxygen, any reduction of this flux, for example during an ischemic episode, will inevitably induce an energetic imbalance, an increase in AMP/ATP ratio and, so, AMPK activation ( ). It has been postulated that this resulting AMPK activation acts as an Figure 5B emergency signal to restore cell energy homeostasis ( ). Indeed, it is assumed that AMPK promotes glycolysis, the sole energy providing 78-81 pathway under anaerobic conditions, by a double mechanism ( ). First, it increases glucose uptake by stimulating the translocation of Figure 5B glucose transporter GLUT4 to the sarcolemmal membrane. Second, AMPK indirectly stimulates 6-phosphofructo-1-kinase (PFK-1) activity by phosphorylating and activating 6-phosphofructo-2-kinase, the enzyme that synthesizes fructose 2,6-bisphosphate, a potent PFK-1 stimulator.
By participating in the stimulation of glycolysis and, so, in the ATP production, AMPK is considered to play a protective role during an ischemic episode. By contrast, it has been postulated that AMPK could play a deleterious role during early reperfusion. Indeed, during reperfusion, the still existing AMPK activation helps fatty acid oxidation to predominate over glucose oxidation by phosphorylating and inactivating ACC. This ACC inactivation decreases the concentration of malonyl-CoA and so increases fatty acid oxidation ( ). Figure 5C During the early phase of reperfusion, this resulting stimulation of fatty acid oxidation occurs in parallel to the still present glycolytic stimulation, inducing a deleterious uncoupling of glucose oxidation and glycolysis ( ). Transgenic animal models have been extensively used 78
to answer to the question if AMPK is a friend or a foe for the heart during an ischemia/reperfusion episode. The study of AMPK 2 / mouse α − − heart ( ), the AMPK 2 isoform being predominant in the heart, and of AMPK 2-KD mice where a kinase-dead AMPK 2 isoform (K45Rof the AMPK 2 isoform, ACC phosphorylation in both normoxic and ischemic conditions was clearly decreased ( between modifications of metabolic regulation and heart function is difficult to establish, these results, taken together, showed that the decrease of AMPK activation is detrimental for the heart during ischemia.
However, the effect of AMPK activity deletion on the heart function during reperfusion is less clear. However, it should be mentioned that the relationship between glycogen storage and AMPK is not simply related to its activity/activation. phosphorylation of ion channels. Similarly to these AMPK mutations, the cardiac-specific dominant-negative TAK1 mice were characterized γ by electrophysiological and biochemical properties similar to WPW syndrome and impaired AMPK activation ( ). The author of this study 92
concluded that TAK1 plays a pivotal role in the LKB1/AMPK signaling.
Finally, the study of genetic models of AMPK revealed new roles for this enzyme. Indeed, using AMPK 2-KD, it has been recently α reported that AMPK plays an important role in p38 MAPK activation during ischemia by promoting p38 MAPK autophosphorylation through interaction with the protein TAB1 ( ). On the same way, in the heart AMPK 2i model ( ), it has been shown that AMPK mediates cardiacpreconditioning by regulating the activity and recruitment of sarcolemmal K(ATP) channels ( ). On the other hand, the study of AMPK 2 / 94 α − − mouse heart revealed that AMPK 2 participates in the regulation of cardiac muscle oxidative capacity ( ). The absence of AMPK 2 induced α 95 α the decrease of the maximal oxidative capacity and an impairment of the complex I of the respiratory chain. This was associated to a decrease in mitochondrial cardiolipin content that could be explained by the downregulation of mRNA of enzymes involved in cardiolipin synthesis and remodeling. induce aortic relaxation in mice, in an endothelium and eNOS-independent manner. AMPK activation may be an additional mechanism by which hypoxia or metabolic challenge can induce vasorelaxation of large vessels, thereby increasing oxygen availability in peripheral tissues.
Role of AMPK in vascular reactivity
AMPK thus appears as a new player in the complex signaling pathways that regulate vascular tone.
Role of AMPK in the hypothalamus
The central nervous system, in particular the hypothalamus, plays an essential role in the regulation of feeding behavior and energy expenditure by integrating information from the periphery through nutrients, hormones and afferent neural inputs ( ). The emerging role of 103 hypothalamic AMPK in these pathways involved in whole body energy homeostasis has received considerable attention during the last years ( ), highlighting a more central and integrated function for AMPK than the one primarily recognized as cellular energy sensor. The most [104] [105] [106] striking proof of concept for AMPK involvement in appetite regulation came from experiments showing that expression of a constitutively active or a dominant negative form of AMPK in the hypothalamus induced reciprocal modifications of neuropeptides expression, food intake and body weight in mice ( ). Thus, elevated hypothalamic AMPK activity led to stimulation of food intake whereas its reduction was 107 associated with hypophagia. In agreement with this genetic approach, it has been shown that acute intracerebroventricular (icv) administration of pharmacological AMPK activator (AICAR) or inhibitor (compound C) increased or decreased food intake, respectively ( , ). 108 109 Furthermore, antagonistic effects on food intake were also observed after modulation of intra-hypothalamic ATP levels by icv injection of 2-deoxyglucose (orexigen, ( )) or the fatty acid synthase inhibitor C75 (anorexigen, ( )). Interestingly, a number of studies demonstrated 110 111 that hypothalamic AMPK is also regulated under physiological conditions, its activation during starvation and inactivation upon refeeding being associated with nutritional changes in circulating hormones and nutrients ( , ). Thus, it has been shown that hormones known to 107 111 affect food intake could exert part of their effects through modulation of hypothalamic AMPK activity. The adipocytokine leptin and insulin, which exert anorexigenic effects, were reported to inhibit AMPK in both arcuate (ARC) and paraventricular hypothalamic nucleus by a mechanism that presumably involved the melanocortin 4 receptors ( ). In other hand, the gut hormone ghrelin induced hypothalamic AMPK 107 activation and stimulation of food intake ( , ). Furthermore, it has been very recently demonstrated that trimeric and hexameric forms of 108 112 adiponectin were able to cross the blood brain barrier and to concomitantly increase AMPK activity in ARC nucleus and food intake in mice ( decade, it has been recently shown that the hypophagia following icv injection of glucose could be mediated by suppression of AMPK activity in multiple hypothalamic areas ( , ). Thus, AMPK is physiologically inhibited by elevated glucose level associated with refeeding and 107 109 activated by a reduction of glucose availability during prolonged fasting.
The mammalian target of rapamycin (mTOR) has been recently implicated in the hypothalamic control of food intake. However, conversely to AMPK, mTOR is activated by leptin, glucose and amino acids, leading to inhibition of food intake ( ). Interestingly, since 117 activation of AMPK suppresses mTOR activity, this strongly suggests that both kinases may have overlapping and reciprocal functions in the control of feeding behavior (
). The AMPK-mediated regulation of food intake involves complex modifications of orexigenic and 117 anorexigenic neuropeptides expression, notably in the ARC nucleus of the hypothalamus, a region containing both neuropeptides Y (NPY)/agouti-related protein (AgRP) and pro-opiomelanocortin (POMC)/cocaine-and amphetaminregulated transcript (CART) neurons.
Indeed, inhibition of hypothalamic AMPK was reported to suppress neuronal NPY/AgRP signaling ( ), this being eventually mediated by a 107 cAMP response element-binding protein (CREB)-dependent mechanism ( ), whereas elevated AMPK activity was associated with increased 111 fasting-induced NPY and AgRP expression ( , ). However, the underlying mechanism(s) connecting modulation of hypothalamic AMPK 107 110 activity to expression of these neuropeptides remain unknown to date. It has been suggested that modulation of malonyl-CoA and/or long chain fatty acyl-CoA (LCFA-CoA) concentrations in the hypothalamus could act as potent regulators of food intake ( , ). Accordingly, AMPK 118 119 activation during starvation, which leads to phosphorylation and inactivation of ACC, would decrease hypothalamic malonyl-CoA and/or LCFA-CoA content, favor fatty acid oxidation and stimulate feeding ( ). Since AMPK has been shown to phosphorylate and activate Figure 7 malonyl-CoA decarboxylase (MCD) ( ), this could also participate to the reduction of malonyl-CoA level by increasing its degradation. In 120 support to this mechanism, CPT1 inhibition ( ) and adenovirus-mediated expression of MCD in the hypothalamus ( ) have been 121 122 associated with opposite changes in malonyl-CoA levels and neuropeptides expression, resulting in suppression or stimulation of food intake, respectively. Although recent evidence suggests that the brain-specific CPT1 isoform (CPT1c) may be one of the hypothalamic malonyl-CoA target that relays AMPK signaling to orexigenic and anorexigenic neurons ( ), further studies will be needed to address this specific issue. In 123 addition, the signal resulting from hypothalamic lipid sensing could come from LCFA itself since it has been reported that icv administration of fatty acids or manipulation of hypothalamic lipid metabolism also reduced food intake ( ). 121
Taken together, there is a growing body of evidence suggesting that hypothalamic AMPK plays a key role in appetite regulation by integrating nutrient-and hormonal-derived signals. However, it is striking that neither the AMPK 1 nor the AMPK 2 knockout mice exhibited α α apparent changes in body weight and mean daily food intake (( , ) and ). While upregulation of the remaining AMPK isoforms 17 18 Table 2 should not be excluded, as previously reported in other tissues ( ), it should be noted that these phenotype were observed on animals fed a 18 normal chow diet and may eventually differ in response to other diets ( high fat). In addition, it would also be interesting to ad libitum e.g. measure food intake during the first hours following refeeding in mice submitted to a prolonged fasting period to see if the starvation-induced activation of AMPK in the hypothalamus is involved in the initiation of food intake. Finally, the forthcoming generation of mice expressing neuron-specific deletion of 1 and 2 isoforms of the AMPK catalytic subunits in specific regions of the hypothalamus would probably α α constitute a very helpful model to further study the involvement of AMPK in feeding behavior and energy expenditure. Thus, very recent results showed that newly engineered mice lacking AMPK 2 in POMC neurons unexpectedly developed obesity due to reduction of energy α expenditure and dysregulation of food intake ( ). In other hand, deletion of AMPK 2 in AgRP neurons led to divergent physiological effect, 124 α the development of an age-dependent lean phenotype ( ). These new opposite findings would certainly lead to a higher degree of i.e. 124
complexity with regard to the role of AMPK in hypothalamic functions. unique AMPK -subunit in has been also generated and showed a lethal phenotype ( , ), demonstrating the necessity of 
New insights in AMPK functions from non-mammalian animal model systems Drosophila
MRLC mutant containing phosphomimetic residues replacing the residues phosphorylated by AMPK rescued both cell polarity and mitosis defects in AMPK-and LKB1-null fly mutants ( ). These findings uncovered a link between energy status and cell structures, revealing new 127 pathophysiological functions for AMPK signaling pathway.
*Caenorhabditis elegans
Senescence in is associated with changes in cellular AMP/ATP ratio suggesting a link between genes known to affect lifespan C. elegans and the control of energy metabolism in worms (
). Over-expression of the AMPK catalytic subunit increases lifespan ( ). 131 C. elegans
The generation of mutants in has also highlighted the role of AMPK in the regulation of lifespan in response to environmental stress C. elegans and insulin-like signaling ( ). Environmental stresses such as starvation, heat shock or mutations that inactivate genes involved in insulin 132 signaling extend life span only in worms expressing aak-2, which is one of the two catalytic subunits of AMPK in ( , ). It has C. elegans 131 133 been recently demonstrated that AMPK is required for mediating lifespan extension by dietary restriction in worms via the phosphorylation of the FOXO transcription factor DAF-16 ( ). Interestingly, AMPK also phosphorylates human FOXO3 in mammalian cells, indicating that the 134 regulation of FOXO by AMPK may be conserved ( ). Thus, these studies raise the intriguing possibility that AMPK may also be implicated 135 in the increase in life span induced by caloric restriction in mammals. Indeed, resveratrol, a polyphenol that activates AMPK, has been shown to mitigate effects of high-calorie and high-fat diets in mice by improving lifespan ( ). 22
Action of anti-diabetic drugs on the AMPK pathway
Since it has been shown that AMPK could be involved in the anti-diabetic effect of metformin ( ), numbers of studies have used AMPK 136 activators to investigate putative treatments against insulin resistance and diabetes. For example, it has been shown that AMPK activation by oligomycin or metformin was able to re-establish a normal insulin-sensitivity in insulin-resistant cardiomyocytes ( ). In this last study, the 137 putative role of AMPK was re-enforced by the use of a constitutively active form of AMPK that mimicked the effects of AMPK activators. But caution is required when interpreting findings on the sole basis of treatment with AICAR, oligomycin or metformin as these widely used pharmacological AMPK activators are not necessarily completely specific for AMPK activation. It has been recently demonstrated using mice lacking both 1 and 2 catalytic subunits in the liver that AICAR and metformin have detrimental effects on energy metabolism by their decreased activity of PPAR signaling pathways in the liver which may contribute to reduced insulin sensitivity in these mice ( ). These α 147 different KO mice models indicates that functional differences exist in adiponectin-signaling pathways in the liver, AdipoR1 being tightly linked to activation of AMPK pathways whereas AdipoR2 being more associated with the activation of PPAR-pathways ( , ).
However, the link between adiponectin and AMPK is more convincing in heart pathologies like hypertrophy. Indeed, it has been shown that pressure overload in adiponectin KO mice resulted in enhanced hypertrophy associated with a decreased AMPK signaling ( ). In 148 cardiomyocytes, adiponectin was able to induce AMPK activation concomitantly to the inhibition of an agonist-stimulated hypertrophy ( ). 148
The fact that the expression of a dominant-negative form of AMPK reversed these effects revealed a clear implication of the AMPK signaling in the putative adiponectin role as treatment against cardiac hypertrophy.
Perspectives
While the primary targets for AMPK have been involved mainly in the control of energy metabolism ( ), new evidence indicates that 16
AMPK also participates in the control of non-metabolic processes such as regulation of mitotic cell division, cell growth, progression through the cell cycle and organization of the cytoskeleton. Thus, AMPK signaling pathway has evolved into a highly complex system which integrates multiple signals from cellular environment to ensure that all highly energy-consuming cellular functions only proceed if cells have sufficient metabolic resources. Thus, the key role of AMPK in maintaining energy balance places it as an ideal therapeutic target for the treatment of derangements of energy metabolism that occur in conditions like obesity, insulin resistance, type 2 diabetes and the metabolic syndrome but also cancer. Different specific and non-specific AMPK activators have been employed with promising results in animal models with obesity or type 2 diabetes ( , ), but, on the other hand, caution should be exercised for the design of clinical trials. Difficulties in clinical applications 16 139 may be multifactorial. Experimental animal models are not fully reliable and reproduce at least some aspects of human disease. Expression and activation pattern of AMPK isoforms differs between rodent and human muscle and between muscle fiber types ( , ). Furthermore, sex 149 150 difference in muscle AMPK activation has been observed in human, probably due to sex specific muscle morphology (higher proportion of type 1 muscle fibers in women) ( ). Inclusion of these criteria should be accurately discussed to better define the population most likely to 151 benefit from AMPK-based therapeutic strategies.
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Figure 6
Effect of AMPK 2 or LKB1 deletion on glycogen content and lactate production in normoxic and ischemic hearts Proposed model for the role of AMPK in the hypothalamic control of food intake The activation of AMPK in the hypothalamus during starvation and its inactivation upon refeeding are mediated by nutritional changes in circulating hormones and nutrients. Ghrelin and adiponectin, which stimulate food intake, activate hypothalamic AMPK, whereas glucose, insulin, leptin and presumably resistin, which are known to inhibit food intake, inhibit it. Once activated, AMPK phosphorylates and inactivates ACC. The expected consequences are elevated malonyl-CoA concentration, leading to subsequent inhibition of mitochondrial fatty acid oxidation, and increased level of LCFA-CoA. The hypothalamic integration of these signals results in opposite changes in orexigenic/anorexigenic neuropeptides expression and subsequent modification of food intake. The underlying mechanism(s) upstream and downstream AMPK remain to be identified.
ACC, acetyl-CoA carboxylase; ACS, acyl-CoA synthetase; AMPK, AMP-activated protein kinase; CPT-1, carnitine palmitoyl transferase 1; FAS, fatty acid synthase; MCD, malonyl-CoA decarboxylase; mTOR, mammalian target of rapamycin. Table 1  Table 1A . Genetic animal models for the study of AMPK signaling pathway Animal model Tissue specificity Remarks Reference Knock-out mice Ad, adenovirus; Alfp, albumin -fetoprotein; AgRP, agouti-related protein; Cre, Cre recombinase; MCK, muscle creatine kinase; POMC, pro-opiomelanocortin; -MHC, -myosin heavy chain; AMPK 1-CA, 
Table 2
Body weight, food intake, 24h-respiratory quotient and energy expenditure in AMPK 1 / and AMPK 2 / mice during fasted and fed periods. 
